CEBP CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leitzmann, M. F.
Right arrow Articles by Giovannucci, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leitzmann, M. F.
Right arrow Articles by Giovannucci, E.
Cancer Epidemiology Biomarkers & Prevention Vol. 11, 1108-1111, October 2002
© 2002 American Association for Cancer Research

Short Communications

Aspirin Use in Relation to Risk of Prostate Cancer1

Michael F. Leitzmann2,,3, Meir J. Stampfer3, Jing Ma3, June M. Chan4, Graham A. Colditz3, Walter C. Willett5 and Edward Giovannucci3

Departments of Epidemiology [M. F. L., M. J. S., G. A. C., W. C. W., E. G.] and Nutrition [M. F. L., M. J. S., W. C. W., E. G.], Harvard School of Public Health, Boston, Massachusetts 02115; Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts 02115 [M. F. L., M. J. S., J. M., G. A. C., W. C. W., E. G.]; Harvard Center for Cancer Prevention, Boston, Massachusetts 02115 [G. A. C.]; Epidemiology Program, Dana Farber/Harvard Cancer Center, Boston, Massachusetts 02115 [G. A. C.], and Departments of Epidemiology and Biostatistics & Urology, University of California, San Francisco, California [J. M. C.]


   Abstract
Top
 Abstract
Introduction
 Patients and Methods
 Results
 Discussion
 References
 
Experimental studies have shown inhibitory effects of nonsteroidal anti-inflammatory drugs on prostate cancer cell proliferation and reduction of prostate cancer metastasis, suggesting their possible preventive role for prostate cancer. We examined the association between regular aspirin use and the risk of prostate cancer among participants in the Health Professionals Follow-up Study, a prospective cohort of 47,882 United States men who were 40–75 years of age and without a history of prostate cancer in 1986. Biennial self-administered questionnaires were used to assess regular aspirin use from 1986 to 1996. We confirmed and staged incident cases of prostate cancer according to medical records and pathology reports. During 518,072 person-years of follow-up, 2,479 new cases of prostate cancer were ascertained. Of these, 608 were diagnosed as advanced (extraprostatic) prostate cancer and 258 as metastatic prostate cancer. We found no association between aspirin use and total prostate cancer. After accounting for prostate-specific antigen examinations and other potentially confounding variables, the relative risk of total prostate cancer for aspirin users compared with nonusers was 1.05 (95% confidence interval, 0.96–1.14). For metastatic prostate cancer, we observed a suggestive decrease in risk among men reporting greater frequency of aspirin use. The multivariate relative risk of metastatic prostate cancer among men using aspirin 22 or more days/month was 0.73 (95% confidence interval, 0.39–1.38) compared with nonusers. We noted no evidence of a linear dose-response relationship (P for trend = 0.40). The results from this cohort indicate that regular aspirin use is not likely to prevent the incidence of total prostate cancer, but we cannot exclude a possible benefit of frequent aspirin use on risk of developing metastatic prostate cancer.


   Introduction
Top
 Abstract
 Introduction
Patients and Methods
 Results
 Discussion
 References
 
Aspirin and other NSAIDs6 are hypothesized to play a role in the chemoprevention of prostate carcinogenesis by inhibiting the activity of COXs, key enzymes that catalyze the formation of prostaglandins from arachidonic acid (1) . Evidence shows that COX-2 is up-regulated in human prostate cancer, and that COX-2 levels correlate positively with prostate tumor grade (2) . Enhanced levels of prostaglandin E2 (3) and its precursor arachidonic acid (4) stimulate prostate tumor growth, and COX-2 inhibitors suppress prostate tumor growth in rats (5) as well as in human prostate tumor-derived cell lines (6) . Animal studies suggest that aspirin may reduce metastasis of prostate cancer but has less influence on prostate tumor volume (7) , suggesting that aspirin may more strongly suppress cellular growth for aggressive prostate cancer than for slowly growing prostate tumors.

Despite fairly consistent laboratory evidence in support of the hypothesis that NSAIDs inhibit the development of prostate cancer, epidemiological data concerning the relationship between NSAID use and risk of prostate cancer are inconclusive. Five cohort studies (8, 9, 10, 11, 12) and two case-control studies (13 , 14) found inverse associations between NSAID use and prostate cancer risk. Two of these studies (12 , 13) suggest a benefit of aspirin use on fatal or advanced prostate cancer. In contrast, three case-control studies (15, 16, 17) reported moderate positive relationships between NSAID use and prostate cancer risk. Overall, the epidemiological data suggest both an increased likelihood of aspirin users being diagnosed with early-stage prostate cancer as well as a benefit of long-term aspirin use on risk of developing advanced prostate cancer.

Because the relationship between NSAID use and prostate cancer remains unresolved, we examined prospectively the association between regular use of aspirin and subsequent risk of prostate cancer in the Health Professionals Follow-up Study, a large cohort of United States men with detailed data on aspirin use, screening behaviors, and clinical staging of cancer outcomes.


   Patients and Methods
Top
 Abstract
 Introduction
 Patients and Methods
Results
 Discussion
 References
 
Study Population.
The Health Professionals Follow-up Study was established in 1986 when 51,529 United States male health professionals between the ages of 40 and 65 years returned a detailed mailed questionnaire concerning their history of medical conditions, medication use, diet, and lifestyle factors. Since then, follow-up questionnaires have been mailed biennially to update information on potential risk factors and to identify newly diagnosed illnesses.

Assessment of Aspirin Use.
Regular use of aspirin was assessed in 1986 and every 2 years thereafter by asking participants to report whether they currently took "any of the following medications two or more times per week" and listed "aspirin (e.g., Anacin, Bufferin, Alka-Seltzer)," among other drugs. Starting in 1992, the questionnaire included a more detailed assessment of aspirin use. Respondents were asked to report the average number of days each month aspirin was taken (none, 1–4, 5–14, 15–21, or 22 or more).

Identification of Cases of Prostate Cancer.
On each biennial questionnaire, participants were asked whether they had been diagnosed with prostate cancer during the prior 2 years. For those who reported prostate cancer, we requested permission to obtain hospital records and pathology reports. For deceased men, we contacted next of kin for this approval. A study physician reviewed all medical records and staged prostate cancers according to information received from medical reports.

Data Analysis.
We calculated person-time of follow-up for each participant from the date of return of the 1986 questionnaire to the date of prostate cancer diagnosis, death, or the end of the study period in 1998, whichever came first. The age-adjusted RR was calculated using the Mantel-Haenszel method. Multivariate RRs were computed using Cox proportional hazards regression modeling.


   Results
Top
 Abstract
 Introduction
 Patients and Methods
 Results
Discussion
 References
 
We examined three different prostate cancer outcomes (total, advanced, and metastatic). For total prostate cancer, a weak positive relation was observed among men reporting regular aspirin use at baseline in 1986 compared with nonusers (multivariate RR, 1.10; 95% CI, 1.01–1.19; Table 1Citation ). For advanced and metastatic prostate cancer, no significant relationships were evident for aspirin use versus nonuse, although for metastatic cancer a suggestive but nonsignificant inverse association was found when we compared men reporting consistent aspirin use with men consistently not using aspirin (multivariate RR, 0.71; 95% CI, 0.31–1.62).


View this table:
[in this window]
[in a new window]
  		Table 1 RR of prostate cancer in relation to aspirin use in the Health Professionals Follow-up Study

 
Because enhanced medical surveillance among aspirin users may decrease their likelihood of being diagnosed with metastatic prostate cancer, we repeated the analyses after excluding noncases who had not had an examination including PSA values by 1994 (52% of person-time excluded). Using consistent nonusers of aspirin as the reference group, the multivariate RRs of total, advanced, and metastatic prostate cancer associated with consistent aspirin use were 0.91 (95% CI, 0.76–1.11), 0.89 (95% CI, 0.57–1.39), and 0.63 (95% CI, 0.27–1.46), respectively.

We addressed the dose-response relation by evaluating the association between increasing frequency of aspirin use, which was first assessed in 1992, and prostate cancer risk (Table 2)Citation . For total and advanced prostate cancer, essentially null associations were found for any given level of aspirin use when compared with nonuse of aspirin. For metastatic prostate cancer, a statistically nonsignificant lower risk was seen when we compared extreme categories of frequency of aspirin use (multivariate RR comparing men using aspirin on 22+ days/month with nonusers, 0.73; 95% CI, 0.39–1.38). No evidence of a linear trend was noted (P for trend = 0.40).


View this table:
[in this window]
[in a new window]
  		Table 2 RR of prostate cancer in relation to frequency of aspirin use (days/month) in the Health Professionals Follow-up Study, 1992–1998

 
After excluding noncases who had not had a PSA examination by 1994, the multivariate RRs of metastatic prostate cancer across increasing days/month of aspirin use (0–4, 5–14, 15–21, and 22+) were 1.00, 0.87, 1.07, and 0.64 (95% CI, 0.33–1.22), respectively (P for trend = 0.22).


   Discussion
Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
References
 
In this prospective study, we observed no association between aspirin use and overall prostate cancer incidence. Because of the possibility that aspirin more strongly suppresses cellular growth for aggressive tumors than for slowly growing tumors, we specifically addressed the relation of aspirin use to risk of metastatic prostate cancer. We observed a statistically nonsignificant inverse relation of consistent aspirin use on 22+ days/month, as reported on consecutive questionnaires, with metastatic prostate cancer risk.

A possible explanation of this finding is that aspirin users undergo screening more frequently, leading to diagnosis of prostate cancer at an earlier stage. However, the inverse relation with metastatic prostate cancer persisted when examinations including PSA values were taken into account. Of note, our group has observed the same pattern for genetic and constitutional features, such as a polymorphism in the androgen receptor gene, plasma insulin-like growth factor I levels, and height, which are nonbehavioral factors that are unlikely to be prone to detection bias.

Our findings are consistent with most previous cohort studies (8, 9, 10 , 12) examining the association between NSAID use and prostate cancer, which found weak inverse and statistically nonsignificant associations (RRs between 0.82 and 0.95) between aspirin or NSAID use and risk of total prostate cancer. Our results are also compatible with those from one case-control study examining regular use of low-dose aspirin (13) , which reported an OR of 0.84 for total prostate cancer and an OR of 0.69 for advanced prostate cancer, suggestive of a stronger benefit of aspirin use on advanced prostate cancer.

One cohort study (11) and one case-control study (14) reported strong inverse associations (ORs between 0.34 and 0.45) between regular daily NSAID intake and risk of total prostate cancer. The former study (11) comprised men with a high level of surveillance for prostate cancer and found a stronger apparent protective effect of NSAIDs among older men (OR, 0.17), suggesting that NSAIDs may prevent the progression of preclinical disease to clinically detectable cancer. In the latter study (14) , controls were healthy men who underwent prostate screening, possibly a group enriched with health-seeking behaviors, thereby biasing the results in favor of a protective effect of NSAIDs. The results for total prostate cancer in these two studies (11 , 14) were markedly different from all other available data (8, 9, 10 , 12 , 13 , 15, 16, 17) .

Three case-control studies (15, 16, 17) found increased risks of total prostate cancer (ORs between 1.28 and 1.60) with greater number of NSAID prescriptions. However, the positive relationships in these studies may have been attributable to detection bias, because men needed to see a doctor to receive a NSAID prescription. Moreover, use of over-the-counter NSAIDs were not taken into consideration (15, 16, 17) , and the exposure definition may have included NSAIDs with little anti-inflammatory activity (16 , 17) .

An inverse association between aspirin use and metastatic prostate cancer is supported by laboratory studies showing that NSAIDs suppress prostate cancer cell growth, apparently through an induction of apoptosis (18) . The inhibition of prostate cancer metastasis by NSAIDs may involve several pathways, including inhibition of enzymatic degradative processes of prostate tumor cell invasiveness (19) , down-regulation of vascular endothelial growth factor expression (20) and decreased angiogenesis in prostate cancer cells (21) , activation of transcription factors such as peroxisome proliferator-activated receptor {gamma} (22) , potentially resulting in antiproliferative effects in PC-3 cell lines (23) , and inhibition of androgen receptor transcriptional activity in LNCaP cells (24) .

In summary, our results among United States men do not support the hypothesis that regular aspirin use prevents the incidence of total prostate cancer. However, the suggestion of a potential decrease in the risk of metastatic prostate cancer among frequent users of aspirin warrants further study.


   Acknowledgments
 
We are indebted to Mira Koyfman, Mildred Wolff, Elizabeth Frost-Hawes, Barbara Vericker, and Jill Arnold for expert help.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by Research Grants CA55075 and HL35464 from the NIH and Cancer Epidemiology Training Grant 5T32 CA09001-26 (to M. F. L.) from the National Cancer Institute. Back

2 To whom requests for reprints should be addressed, at Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115. Phone: (617) 432-4220; Fax: (617) 432-2435; E-mail: michael.leitzmann{at}channing.harvard.edu Back

3 Present address: Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115. Back

4 Present address: Departments of Epidemiology and Biostatistics & Urology, University of California, San Francisco, 333 California Street, Suite 280, San Francisco, CA 94143. Back

5 Present address: Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115. Back

6 The abbreviations used are: NSAID, nonsteroidal anti-inflammatory drug; COX, cyclooxygenase; RR, relative risk; CI, confidence interval; PSA, prostate-specific antigen; OR, odds ratio. Back

Received 1/11/02; revised 5/15/02; accepted 5/29/02.


   References
Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 

  1. Vane J. R., Bakhle Y. S., Botting R. M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol., 38: 97-120, 1998.[Medline]
  2. Madaan S., Abel P. D., Chaudhary K. S., Hewitt R., Stott M. A., Stamp G. W., Lalani E. N. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int., 86: 736-741, 2000.[Medline]
  3. Shaw M. W., Ablin R. J., Ray P., Rubenstein M., Guinan P. D., McKiel C. F. Immunobiology of the Dunning R-3327 rat prostate adenocarcinoma sublines: plasma and tumor effusion prostaglandins. Am. J. Reprod. Immunol. Microbiol., 8: 77-79, 1985.[Medline]
  4. Chaudry A., McClinton S., Moffat L. E., Wahle K. W. Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br. J. Cancer, 64: 1157-1160, 1991.[Medline]
  5. Wechter W. J., Leipold D. D., Murray E. D., Jr., Quiggle D., McCracken J. D., Barrios R. S., Greenberg N. M. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res., 60: 2203-2208, 2000.[Abstract/Free Full Text]
  6. Rose D. P., Connolly J. M. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate, 18: 243-254, 1991.[Medline]
  7. Drago J. R., Murray C. Control of metastases in the Nb rat prostatic adenocarcinoma model. J. Androl., 5: 265-268, 1984.[Abstract/Free Full Text]
  8. Schreinemachers D. M., Everson R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 5: 138-146, 1994.[Medline]
  9. Paganini-Hill A., Chao A., Ross R. K., Henderson B. E. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ (Clin. Res. Ed.), 299: 1247-1250, 1989.
  10. Bucher C., Jordan P., Nickeleit V., Torhorst J., Mihatsch M. J. Relative risk of malignant tumors in analgesic abusers. Effects of long-term intake of aspirin. Clin. Nephrol., 51: 67-72, 1999.[Medline]
  11. Roberts R. O., Jacobson D. J., Girman C. J., Rhodes T., Lieber M. M., Jacobsen S. J. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clinic Proceed., 77: 219-225, 2002.
  12. Thun M. J., Namboodiri M. M., Calle E. E., Flanders W. D., Heath C. W., Jr. Aspirin use and risk of fatal cancer. Cancer Res., 53: 1322-1327, 1993.[Abstract/Free Full Text]
  13. Norrish A. E., Jackson R. T., McRae C. U. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int. J. Cancer, 77: 511-515, 1998.[Medline]
  14. Nelson J. E., Harris R. E. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol. Rep., 7: 169-170, 2000.[Medline]
  15. Neugut A. I., Rosenberg D. J., Ahsan H., Jacobson J. S., Wahid N., Hagan M., Rahman M. I., Khan Z. R., Chen L., Pablos-Mendez A., Shea S. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol. Biomark. Prev., 7: 869-873, 1998.[Abstract]
  16. Langman M. J., Cheng K. K., Gilman E. A., Lancashire R. J. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ, 320: 1642-1646, 2000.[Abstract/Free Full Text]
  17. Perron L., Moore L., Meyer F. Non-steroidal anti-inflammatory drugs (NSAID) and prostate cancer (PC) risk: a population-based case-control study. Am. J. Epidemiol., 153: S100 2001.
  18. Liu X. H., Yao S., Kirschenbaum A., Levine A. C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res., 58: 4245-4249, 1998.[Abstract/Free Full Text]
  19. Attiga F. A., Fernandez P. M., Weeraratna A. T., Manyak M. J., Patierno S. R. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res., 60: 4629-4637, 2000.[Abstract/Free Full Text]
  20. Liu X. H., Kirschenbaum A., Yao S., Stearns M. E., Holland J. F., Claffey K., Levine A. C. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin. Exp. Metastasis, 17: 687-694, 1999.[Medline]
  21. Liu X. H., Kirschenbaum A., Yao S., Lee R., Holland J. F., Levine A. C. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J. Urol., 164: 820-825, 2000.[Medline]
  22. Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M., Kliewer S. A. Peroxisome proliferator-activated receptors {alpha} and {gamma} are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem., 272: 3406-3410, 1997.[Abstract/Free Full Text]
  23. Kubota T., Koshizuka K., Williamson E. A., Asou H., Said J. W., Holden S., Miyoshi I., Koeffler H. P. Ligand for peroxisome proliferator-activated receptor {gamma} (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res., 58: 3344-3352, 1998.[Abstract/Free Full Text]
  24. Zhu W., Smith A., Young C. Y. A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology, 140: 5451-5454, 1999.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 American Journal of Men's HealthHome page
J. Jayachandran and S. J. Freedland
Prevention of Prostate Cancer: What We Know and Where We Are Going
American Journal of Men's Health, June 1, 2008; 2(2): 178 - 189.
[Abstract] [PDF]

Home page
 CarcinogenesisHome page
X. Wang, J. K.L. Colby, P. Yang, S. M. Fischer, R. A. Newman, and R. D. Klein
The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue
Carcinogenesis, January 1, 2008; 29(1): 120 - 128.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
D. Mazhar, R. Gillmore, and J. Waxman
COX and cancer
QJM, October 1, 2005; 98(10): 711 - 718.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
E. J. Jacobs, C. Rodriguez, A. M. Mondul, C. J. Connell, S. J. Henley, E. E. Calle, and M. J. Thun
A Large Cohort Study of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs and Prostate Cancer Incidence
J Natl Cancer Inst, July 6, 2005; 97(13): 975 - 980.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
E. A. Platz, S. Rohrmann, J. D. Pearson, M. M. Corrada, D. J. Watson, A. M. De Marzo, P. K. Landis, E. J. Metter, and H. B. Carter
Nonsteroidal Anti-inflammatory Drugs and Risk of Prostate Cancer in the Baltimore Longitudinal Study of Aging
Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 390 - 396.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Gupta, V. M. Adhami, M. Subbarayan, G. T. MacLennan, J. S. Lewin, U. O. Hafeli, P. Fu, and H. Mukhtar
Suppression of Prostate Carcinogenesis by Dietary Supplementation of Celecoxib in Transgenic Adenocarcinoma of the Mouse Prostate Model
Cancer Res., May 1, 2004; 64(9): 3334 - 3343.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. A. Garcia Rodriguez and A. Gonzalez-Perez
Inverse Association between Nonsteroidal Anti-inflammatory Drugs and Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., April 1, 2004; 13(4): 649 - 653.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leitzmann, M. F.
Right arrow Articles by Giovannucci, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leitzmann, M. F.
Right arrow Articles by Giovannucci, E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation